MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Galmed Pharmaceuticals Ltd. Operating Expenses 2011-2025 | GLMD
Annual Operating Expenses Galmed Pharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 32.9 M | - | 22.4 M | 12.8 M | 13.4 M | 17.3 M | 10.9 M | 9.14 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.9 M | 9.14 M | 17 M |
Quarterly Operating Expenses Galmed Pharmaceuticals Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.41 M | - | - | - | 5.82 M | - | - | - | 4.7 M | - | - | - | 2.78 M | - | - | - | 2.7 M | - | - | - | 4.22 M | - | - | - | 2.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.41 M | 2.53 M | 4.45 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.86 | 3.08 % | $ 807 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.22 | -1.08 % | $ 249 M |  USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-31.8 M | $ 1.05 | -7.08 % | $ 290 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.27 | -4.88 % | $ 588 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 13.58 | -3.62 % | $ 894 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 216.09 | -1.96 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.14 | -4.15 % | $ 7.55 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 27.1 | -1.51 % | $ 1.75 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 88.16 | 0.19 % | $ 9.1 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
190 M | $ 24.27 | 2.75 % | $ 2.87 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | $ 5.02 | -0.59 % | $ 934 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
18.1 M | $ 1.4 | -3.45 % | $ 2.07 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
512 M | $ 93.87 | -0.99 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | $ 10.8 | - | $ 1.4 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 26.2 | 3.68 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 9.57 | 0.1 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 15.96 | -4.42 % | $ 409 M | USA |
 |
Evogene Ltd.
EVGN
|
28 M | $ 1.07 | -0.51 % | $ 27.9 M | Israel |
 |
Exelixis
EXEL
|
598 M | $ 41.43 | 1.35 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
1.18 B | $ 548.8 | -2.74 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
|
Foghorn Therapeutics
FHTX
|
125 M | $ 4.36 | -1.8 % | $ 239 M | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.39 | 3.91 % | $ 15 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 91.03 | 1.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.85 | -1.72 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 11.36 | -1.47 % | $ 735 M | USA |
 |
Biogen
BIIB
|
5.39 B | $ 174.34 | 0.14 % | $ 25.4 B | USA |